Work

A randomized phase II trial of bevacizumab (BV) plus oral everolimus (EV) versus bevacizumab alone for recurrent or persistent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal cancer (PPC).

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.5546

Authors: William P. Tew, Michael Sill, D. Scott McMeekin, Angeles Alvarez Secord, Albert J. Bonebrake, Jeanne Schilder, Ashley Stuckey, Laurel Rice, Krishnansu Sujata Tewari, Carol Aghajanian

Institutions: Memorial Sloan Kettering Cancer Center, Gynecologic Oncology Group, University of Oklahoma Health Sciences Center, Duke Medical Center, Cancer Research for the Ozarks, Indiana University Indianapolis, Women & Infants Hospital of Rhode Island, University of Wisconsin–Madison, University of California, Irvine Medical Center

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2593902747

Cites:

Cited by: 5

Related to: 10